Novel insights into the management of rheumatoid arthritis: one year in review 2022

Clin Exp Rheumatol. 2022 Jul;40(7):1247-1257. doi: 10.55563/clinexprheumatol/1sjgyr. Epub 2022 Jul 4.

ABSTRACT

New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last year. Specifically, updated guidelines on pharmacological and non-pharmacological management of RA have emphasised the necessity of global patient's care, and have shifted the role of some older drugs, such as glucocorticoids and methotrexate. In addition, the long-term safety of Janus kinase inhibitors was investigated and reinforced. With respect to the coronavirus-19 pandemic, reassuring data on the efficacy and safety of vaccinations in the RA population were acquired, as well as on the potential role of telemedicine in RA management. Machine learning prediction models and biomarkers development have emerged as promising innovations in the area of precision/personalised medicine, appearing to encourage future expansion.In this narrative review, the authors aim to give their specific point of view on the most relevant and potentially impacting novelties published during 2021 and early 2022 in the context of RA management.

PMID:35801648 | DOI:10.55563/clinexprheumatol/1sjgyr